Pure Global
NCT06008093

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients

A Phase IIIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Non-Squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON).
AstraZeneca·Phase 3·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Carcinoma, Non-Small-Cell Lung
Drug/Device/Intervention
Durvalumab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
AstraZeneca
Timeline & enrollment
Phase
Phase 3
Start date
Oct 16, 2023
End date
Oct 22, 2031
Enrollment
280 participants
Primary outcome

Overall survival (OS),OS in subset of randomized participants with STK11 or KEAP1 mutations and/or co-mutations

Summary

The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in
 combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in
 metastatic NSCLC patients with non-squamous histology who have mutations and/or co-mutations
 in STK11, KEAP1, or KRAS.

ICD-10 classifications
Carcinoma in situ: Bronchus and lungSecondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06008093
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06008093 through Pure Global AI's free database. This Phase 3 trial is sponsored by AstraZeneca and is currently Not yet recruiting. The study focuses on Carcinoma, Non-Small-Cell Lung. Target enrollment is 280 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.